Immatics (IMTX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.53
- Estimate
- -$0.48
- Surprise
- -12.1%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Immatics (IMTX) reported a wider loss than forecast — diluted EPS of -$0.53 against the -$0.48 estimate (a 12.1% shortfall).
Coverage in the report window
- Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M Estimate — benzinga, 2026-08-18
Where TrendMatrix's rating stands now
TrendMatrix currently rates IMTX Sell at 5.2/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -12.1% surprise compares with a -1.5% four-quarter average. Next scheduled report: 2026-11-17.
What argues against it
- Quality below floor (2.0 < 4.0)
- Momentum score 2.3/10 — below 4.5 minimum
- Death cross — 50-day MA below 200-day MA
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.79
- Price target
- $15.34
- Stop
- $8.17
- Upside to target
- +74.5%
- Reward-to-risk
- 7.4:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
IMTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.34B
- P/E (fwd)
- -4.3
- 52-week range
- $5.67–$12.41
- Off 52-week high
- 29.2%
- RSI (14)
- 47
- Volume vs avg
- 0.78×
- Score today
- 5.2/10